

## **The Drug Utilization Review Board reviewed the following Therapeutic Categories on September 21, 2006**

The DURB acknowledged that cost is a consideration for all products, and has provided its clinical evaluations for the Department's final decisions on the Preferred Drug List (PDL).

### **Antianginals**

The DUR Board did not recommend preferential consideration for *Ranexa*.

### **Antineoplastics**

The DUR Board recommended preferential consideration for *Sutent*

### **Immune Deficiency Drugs**

The DUR Board recommended preferential consideration for *Vivaglobin*

### **Insulins**

The DUR Board recommended preferential consideration for *Levemir*, but did not recommend preferential consideration for *Apidra*

### **Irritable Bowel Drugs**

The DUR Board recommended preferential consideration for *Zelnorm*, but did not recommend preferential consideration for *Amitiza*

## The Drug Utilization Review Board reviewed the following Therapeutic Categories on September 21, 2006

### Phase V - Supplemental Rebate Drugs

#### Immunomodulators

The DUR Board recommended that the drugs in this class maintain their current PDL status and to include *Orencia* for preferential consideration, which resulted in the following:

<b>Enbrel</b>
<b>Humira</b>
<b>Orencia</b>
<b>Remicade</b>

#### Beta Blockers

The DUR Board recommended that the drugs in this class maintain their current PDL status, which results in preferential consideration for the following:

<b>Acebutolol HCL</b>
<b>Atenolol</b>
<b>Betaxolol HCL Tablet</b>
<b>Bisoprolol Fumarate</b>
<b>Coreg</b>
<b>Labetalol HCL</b>
<b>Levatol</b>
<b>Metoprolol Tartrate</b>
<b>Nadolol</b>
<b>Pindolol</b>
<b>Propranolol HCL Tablet</b>
<b>Sotalol AF</b>
<b>Sotalol HCL</b>
<b>Timolol Maleate Tablet</b>

## **The Drug Utilization Review Board reviewed the following Therapeutic Categories on September 21, 2006**

### **Beta Blocker/Diuretic Combinations**

The DUR Board recommended that the drugs in this class maintain their current PDL status, which results in preferential consideration for the following:

:

<b>Atenolol w/Chlorthalidone</b>
<b>Bisoprolol Fumarate/HCTZ</b>
<b>Corzide</b>
<b>Metoprolol HCT</b>
<b>Propranolol HCL w/HCTZ</b>

### **Biguanide Combinations – Oral Antidiabetic Agent**

The DUR Board recommended that the drugs in this class maintain their current PDL status, which results in preferential consideration for the following:

<b>Glipizide- Metformin HCL</b>
<b>Glyburide-Metformin HCL</b>
<b>Metaglip</b>

### **TZD-Sulfonylurea Combinations**

The DUR Board recommended that the drugs in this class maintain their current PDL status, which results in preferential consideration for *Avandaryl*.

### **TZD-Metformin Combinations**

The DUR Board recommended that the drugs in this class maintain their current PDL status, which results in preferential consideration for the following:

<b>Actoplus Met</b>
<b>Avandamet</b>

### **Thiazolidinediones-Oral Antidiabetics Agents**

The DUR Board recommended that the drugs in this class maintain their current PDL status, which results in preferential consideration for the following:

<b>Actos</b>
<b>Avandia</b>

## **The Drug Utilization Review Board reviewed the following Therapeutic Categories on September 21, 2006**

### **Low Sedating Antihistamines**

The DUR Board recommended that the drugs in this class maintain their current PDL status. This results in preferential consideration for the following:

<b>Clarinex Syrup</b>
<b>Clarinex Tablet</b>
<b>Loratadine Syrup OTC</b>
<b>Loratadine Tabs OTC</b>
<b>Loratadine Reditabs OTC</b>

### **Low Sedating Antihistamines/Decongestant Combinations**

The DUR Board recommended that the drugs in this class maintain their current PDL status. This results in preferential consideration for the following:

<b>Clarinex-D 12 Hour</b>
<b>Clarinex-D 24 Hour</b>
<b>Loratadine-D 24H OTC</b>
<b>Loratadine-D 12H OTC</b>

### **Leukotriene Modifiers**

The DUR Board recommended that the drugs in this class maintain their current PDL status, which results in preferential consideration for the following:

<b>Accolate</b>
<b>Singulair</b>

### **Antiasthmatics**

The DUR Board did not recommend preferential consideration for **Zyflo**

## **The Drug Utilization Review Board reviewed the following Therapeutic Categories on September 21, 2006**

### **New Generation Antidepressants**

The DUR Board recommended that the drugs in this class maintain their current PDL status, which results in preferential consideration for the following:

<b>Budeprion SR</b>
<b>Bupropion HCL</b>
<b>Bupropion HCL SA</b>
<b>Effexor</b>
<b>Effexor XR</b>
<b>Maprotiline HCL</b>
<b>Mirtazapine Tab Soltabs</b>
<b>Mirtazapine Tablet</b>
<b>Nefazodone HCL</b>
<b>Trazodone HCL</b>
<b>Wellbutrin XL</b>

### **Ophthalmic Antihistamines**

The DUR Board recommended that the drugs in this class maintain their current PDL status, which results in preferential consideration for the following:

<b>Elestat</b>
<b>Emadine</b>
<b>Optivar</b>
<b>Patanol</b>
<b>Zaditor</b>

### **Ophthalmic Mast Cell Stabilizers**

The DUR Board recommended that the drugs in this class maintain their current PDL status, which results in preferential consideration for the following:

<b>Alamast</b>
<b>Alocril</b>
<b>Alomide</b>
<b>Crolom</b>
<b>Cromolyn Sodium Ophthalmic</b>

## **The Drug Utilization Review Board reviewed the following Therapeutic Categories on September 21, 2006**

### **Prostaglandin Agonists-Ophthalmics**

The DUR Board recommended that the drugs in this class maintain their current PDL status, which results in preferential consideration for the following:

<b>Lumigan</b>
<b>Travatan</b>
<b>Xalatan</b>

### **Ophthalmic Quinolones**

The DUR Board recommended that the drugs in this class maintain their current PDL status, which results in preferential consideration for the following:

<b>Ciprofloxacin HCL</b>
<b>Ocuflox</b>
<b>Ofloxacin</b>
<b>Quixin</b>
<b>Vigamox</b>
<b>Zymar</b>

### **Sedative Hypnotics**

The DUR Board recommended that the drugs in this class maintain their current PDL status, which results in preferential consideration for the following:

<b>Ambien</b>
<b>Ambien CR</b>
<b>Lunesta</b>
<b>Rozerem</b>
<b>Sonata</b>

## **The Drug Utilization Review Board reviewed the following Therapeutic Categories on September 21, 2006**

### **Serotonin Receptor Agonists**

The DUR Board recommended that the drugs in this class maintain their current PDL status, which results in preferential consideration for the following:

<b>Amerge</b>
<b>Axert</b>
<b>Imitrex</b>
<b>Maxalt</b>
<b>Maxalt MLT</b>
<b>Relpax</b>
<b>Zomig</b>
<b>Zomig ZMT</b>

### **Topical Immunomodulators**

The DUR Board recommended that the drugs in this class maintain their current PDL status, which results in preferential consideration for the following:

<b>Elidel</b>
<b>Protopic</b>

### **Urinary Tract Antispasmodics**

The DUR Board recommended preferential consideration for the following drugs in this class:

<b>Detrol LA</b>
<b>Enablex</b>
<b>Oxybutynin Chloride Syrup</b>
<b>Oxybutynin Chloride Tablet</b>
<b>Oxytrol</b>
<b>Sanctura</b>
<b>Vesicare</b>